baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Teva Pharmaceutical Industries Lt.../ US8816242098 /

2024-04-18 10:10:00 PM	Chg. -0.40	Volume	Bid12:18:09 PM	Ask12:18:09 PM	Market Capitalization	Dividend Y.	P/E Ratio
12.78USD	-3.03%	8.96 mill. Turnover: 94.03 mill.	12.50Bid Size: 100	12.75Ask Size: 200	14.33 bill.USD	-	-

GlobeNewswire 12:10 PM Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable...

GlobeNewswire 04-16 Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...

GlobeNewswire 04-03 Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

GlobeNewswire 03-22 Alvotech Announces Increase in Number of Own Shares

GlobeNewswire 03-20 Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

GlobeNewswire 03-06 iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors

GlobeNewswire 03-05 Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET

GlobeNewswire 02-29 Alvotech Appoints Interim Chief Quality Officer

GlobeNewswire 02-26 Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purc...

GlobeNewswire 02-24 Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interc...

GlobeNewswire 02-21 AdhereTech Announces Appointment of Paul Sekhri to Board of Directors

GlobeNewswire 02-15 Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)

GlobeNewswire 02-08 Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to...

GlobeNewswire 01-31 Orange Grove Bio Sets Sights on Rapidly Emerging Middle East Biotech Ecosystem through New Academic ...

GlobeNewswire 01-29 Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Bios...

GlobeNewswire 01-19 Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04

GlobeNewswire 01-10 STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara

GlobeNewswire 01-03 Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT...

GlobeNewswire 2023-11-29 Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Bios...

GlobeNewswire 2023-11-28 Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update

GlobeNewswire 2023-11-21 Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Hos...

GlobeNewswire 2023-11-14 Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First...

GlobeNewswire 2023-11-13 Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program

GlobeNewswire 2023-11-10 STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelar...

GlobeNewswire 2023-11-07 Alvotech to Present at the Jefferies 2023 London Healthcare Conference

Teva Pharmaceutical Industries Lt.../ US8816242098 /

If you wish to receive reply to your feedback, please provide your email address.